Literature DB >> 24266915

Cholestatic liver disease.

Andrea A Gossard1, Jayant A Talwalkar.   

Abstract

The care of the patient with cholestasis hinges on identifying the etiology, treating reversible causes, and managing chronic cholestatic processes. PBC and PSC are important causes of chronic cholestasis, and are the most common causes of cholestatic liver disease. Effective therapy is available for patients with PBC, whereas none exists for patients with PSC. Awareness of the complications that may be associated with cholestasis and implementing the appropriate management are essential.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile duct obstruction; Biliary tract disease; Cholestasis; Cholestatic liver disease; Primary biliary cirrhosis; Primary sclerosing cholangitis

Mesh:

Year:  2013        PMID: 24266915     DOI: 10.1016/j.mcna.2013.09.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  13 in total

Review 1.  Animal models of biliary injury and altered bile acid metabolism.

Authors:  Valeria Mariotti; Mario Strazzabosco; Luca Fabris; Diego F Calvisi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-11       Impact factor: 5.187

Review 2.  A Systematic Approach to Patients with Jaundice.

Authors:  Bilal Gondal; Andrew Aronsohn
Journal:  Semin Intervent Radiol       Date:  2016-12       Impact factor: 1.513

Review 3.  Bridging cell surface receptor with nuclear receptors in control of bile acid homeostasis.

Authors:  Shuangwei Li; Andrew Ni; Gen-sheng Feng
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

4.  Tamoxifen Ameliorates Cholestatic Liver Fibrosis in Mice: Upregulation of TGFβ and IL6 Is a Potential Protective Mechanism.

Authors:  Dino Šisl; Darja Flegar; Maša Filipović; Petra Turčić; Pavao Planinić; Alan Šućur; Nataša Kovačić; Danka Grčević; Tomislav Kelava
Journal:  Biomedicines       Date:  2022-05-23

Review 5.  Pathogenesis of Kupffer Cells in Cholestatic Liver Injury.

Authors:  Keisaku Sato; Chad Hall; Shannon Glaser; Heather Francis; Fanyin Meng; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2016-07-22       Impact factor: 4.307

6.  In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist.

Authors:  Mathieu Vinken
Journal:  Arch Toxicol       Date:  2018-03-24       Impact factor: 5.153

7.  Silymarin mitigates bile duct obstruction-induced cholemic nephropathy.

Authors:  Mohammad Mehdi Ommati; Omid Farshad; Negar Azarpira; Elmira Ghazanfari; Hossein Niknahad; Reza Heidari
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-04       Impact factor: 3.000

8.  Portal Hypertensive Biliopathy: An Infrequent Cause of Biliary Obstruction.

Authors:  Ricardo Cardoso; Adriano Casela; Sandra Lopes; Cláudia Agostinho; Paulo Souto; Ernestina Camacho; Nuno Almeida; Sofia Mendes; Dário Gomes; Carlos Sofia
Journal:  GE Port J Gastroenterol       Date:  2015-03-18

9.  Quality of life in adults with lymphedema cholestasis syndrome 1.

Authors:  Kristin Iversen; Lill Monica Drivdal; Kristin J Billaud Feragen; Amy Østertun Geirdal
Journal:  Health Qual Life Outcomes       Date:  2018-07-25       Impact factor: 3.186

10.  Protective Effects of Peroxiredoxin 4 (PRDX4) on Cholestatic Liver Injury.

Authors:  Jing Zhang; Xin Guo; Taiji Hamada; Seiya Yokoyama; Yuka Nakamura; Jianbo Zheng; Nozomu Kurose; Yasuhito Ishigaki; Hidetaka Uramoto; Akihide Tanimoto; Sohsuke Yamada
Journal:  Int J Mol Sci       Date:  2018-08-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.